TNFRSF17 and plasma cell myeloma: These 55 patients had received a median of five prior anti-myeloma therapies, 50 (90.9%) patients had triple-class refractory myeloma, 32 (58.2%) patients had penta-drug refractory myeloma and a total of 13 (23.6%) patients had received prior BCMA-targeted therapy, including 4 (7.3%) patients who had received BCMA-directed antibody drug conjugate, 5 (9.1%) patients who had received prior anti-BCMA CAR-T and four (7.3%) patients who had received both.